KR20210137025A - 치료제 및 치료 방법 - Google Patents

치료제 및 치료 방법 Download PDF

Info

Publication number
KR20210137025A
KR20210137025A KR1020217028572A KR20217028572A KR20210137025A KR 20210137025 A KR20210137025 A KR 20210137025A KR 1020217028572 A KR1020217028572 A KR 1020217028572A KR 20217028572 A KR20217028572 A KR 20217028572A KR 20210137025 A KR20210137025 A KR 20210137025A
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
independently
ego
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217028572A
Other languages
English (en)
Korean (ko)
Inventor
구앙롱 정
다오홍 조
프래틱 팔
신구이 리우
디네쉬 썸머리
완이 후
페이이 장
동웬 리우
야시아 위안
쉬앤 장
Original Assignee
유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 filed Critical 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드
Publication of KR20210137025A publication Critical patent/KR20210137025A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020217028572A 2019-02-08 2020-02-07 치료제 및 치료 방법 Ceased KR20210137025A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962803299P 2019-02-08 2019-02-08
US62/803,299 2019-02-08
PCT/US2020/017364 WO2020163823A2 (en) 2019-02-08 2020-02-07 Therapeutic agents and methods of treatment

Publications (1)

Publication Number Publication Date
KR20210137025A true KR20210137025A (ko) 2021-11-17

Family

ID=71948254

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217028572A Ceased KR20210137025A (ko) 2019-02-08 2020-02-07 치료제 및 치료 방법

Country Status (8)

Country Link
US (1) US20220169628A1 (https=)
EP (1) EP3920923A4 (https=)
JP (1) JP2022520061A (https=)
KR (1) KR20210137025A (https=)
CN (1) CN113660937A (https=)
AU (1) AU2020218367A1 (https=)
CA (1) CA3127501A1 (https=)
WO (1) WO2020163823A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12441722B2 (en) 2020-01-15 2025-10-14 University Of Florida Research Foundation, Incorporated Therapeutic agents and methods of treatment
WO2022072094A2 (en) * 2020-08-28 2022-04-07 University Of Florida Research Foundation, Incorporated Modulators of nuclear receptor subfamily 4 group a member 1 (nr4a1) and uses thereof
JP2024505562A (ja) 2021-02-02 2024-02-06 レス ラボラトイレス セルビエル 選択的ｂｃｌ－ｘｌ ｐｒｏｔａｃ化合物及び使用の方法
JP2024534223A (ja) 2021-09-01 2024-09-18 シーザン ハイスーク ファーマシューティカル カンパニー リミテッド Ｂｃｌ－２ファミリータンパク質を分解する化合物及びその医薬的な応用
US20240398764A1 (en) * 2021-10-12 2024-12-05 University Of Florida Research Foundation, Incorporated Methods of treating diseases associated with senescent cell accumulation
CA3241668A1 (en) 2021-12-09 2023-06-15 University Of Florida Research Foundation, Incorporated Bcl-xl/bcl-2 dual degraders for treatment of cancers
KR20240128831A (ko) 2021-12-30 2024-08-27 베이진 스위찰랜드 게엠베하 브루톤 티로신 키나아제(btk) 억제제와 e3 리가아제 리간드의 접합에 의한 btk의 분해 및 사용 방법
JP7825122B2 (ja) * 2022-01-04 2026-03-06 上海科技大学 Ｂｃｌ－２ファミリータンパク質リガンド化合物に基づいて開発したタンパク質分解剤及びそれらの応用
EP4519259A1 (en) 2022-05-06 2025-03-12 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
WO2023215449A1 (en) 2022-05-06 2023-11-09 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
EP4519260A1 (en) 2022-05-06 2025-03-12 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-xdegraders
CN115028679B (zh) * 2022-08-11 2022-11-15 深圳湾实验室 一种具有Cyclophilin A降解活性的PROTAC化合物及其制备方法与应用
CN120659777A (zh) * 2022-10-03 2025-09-16 佛罗里达大学研究基金公司 募集Cereblon的Bcl-xL/Bcl-2双重降解剂
WO2024078581A1 (en) * 2022-10-12 2024-04-18 Appicine Therapeutics (Hk) Limited Selective bcl-xl protac compounds and uses thereof
WO2024153185A1 (zh) * 2023-01-18 2024-07-25 苏州宜联生物医药有限公司 包含bcl-2家族蛋白降解剂的抗体药物偶联物及其制备方法和用途
JP2026507476A (ja) * 2023-02-17 2026-03-04 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド トリフルオロメタンスルホニル基を含む化合物
WO2025101575A1 (en) 2023-11-07 2025-05-15 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-x l degraders
TW202535872A (zh) 2023-11-07 2025-09-16 美商樹線生物科學公司 四氫異喹啉異雙功能ｂｃｌ－ｘｌ降解劑
TW202527930A (zh) 2023-11-07 2025-07-16 美商樹線生物科學公司 四氫異喹啉異雙功能ｂｃｌ－ｘｌ降解劑
WO2026015489A1 (en) * 2024-07-08 2026-01-15 University Of Florida Research Foundation, Incorporated Bcl-xl/bcl-2 dual degraders and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973161B2 (en) * 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
JP6817962B2 (ja) * 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． ターゲティングされたアンドロゲン受容体分解のための化合物および方法
EP3270917A4 (en) * 2015-03-18 2018-08-08 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
WO2017024317A2 (en) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US10772962B2 (en) * 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
CN109152933B (zh) * 2016-04-21 2022-12-02 生物风险投资有限责任公司 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
EP3454856B1 (en) * 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2018106870A1 (en) * 2016-12-08 2018-06-14 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cdk4/6-mediated cancer
US20240398764A1 (en) * 2021-10-12 2024-12-05 University Of Florida Research Foundation, Incorporated Methods of treating diseases associated with senescent cell accumulation
CA3241668A1 (en) * 2021-12-09 2023-06-15 University Of Florida Research Foundation, Incorporated Bcl-xl/bcl-2 dual degraders for treatment of cancers

Also Published As

Publication number Publication date
CN113660937A (zh) 2021-11-16
WO2020163823A3 (en) 2020-10-29
EP3920923A4 (en) 2022-10-26
JP2022520061A (ja) 2022-03-28
WO2020163823A2 (en) 2020-08-13
CA3127501A1 (en) 2020-08-13
AU2020218367A1 (en) 2021-08-12
WO2020163823A8 (en) 2020-10-01
EP3920923A2 (en) 2021-12-15
US20220169628A1 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
KR20210137025A (ko) 치료제 및 치료 방법
JP7385284B2 (ja) 癌処置のためのｂｃｌ－２タンパク質分解剤
JP7754865B2 (ja) Ｔｌｒ７／８アンタゴニストおよびそれらの使用
US12441722B2 (en) Therapeutic agents and methods of treatment
CN106255679B (zh) 用作nav通道抑制剂的杂环化合物及其用途
JP7166028B2 (ja) 高活性ｓｔｉｎｇタンパク質アゴニスト化合物
JP2025533170A (ja) 新規な二環式ヘテロシクリル化合物およびその用途
KR20240118146A (ko) 암 치료용 bcl-xl/bcl-2 이중 분해제
CN116783183A (zh) 作为vhl抑制剂用于治疗贫血和癌症的1-(2-(4-环丙基-1h-1,2,3-三唑-1-基)乙酰基)-4-羟基-n-(苄基)吡咯烷-2-甲酰胺衍生物
JP2024178221A (ja) Ｐｄ－ｌ１拮抗薬化合物
JP7281834B2 (ja) Ｐｄ－ｌ１拮抗薬化合物
HK40060209A (en) Therapeutic agents and methods of treatment
RU2823231C1 (ru) Соединение-антагонист PD-L1
HK40074265A (en) Therapeutic agents and methods of treatment
HK40038404A (en) Bcl-2 proteins degraders for cancer treatment
HK40038404B (en) Bcl-2 proteins degraders for cancer treatment
HK1262126B (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
HK1262126A1 (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
HK1231864A1 (en) Heterocyclic compounds as nav channel inhibitors and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210906

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20250207

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250410

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D